Cytokinetics Inc. (NASDAQ:CYTK) shares fell 1.3% on Monday . The stock traded as low as $9.72 and last traded at $9.76, with a volume of 129,619 shares. The stock had previously closed at $9.89.

Several brokerages have recently weighed in on CYTK. Roth Capital restated a “buy” rating on shares of Cytokinetics in a report on Saturday, April 30th. FBR & Co restated a “buy” rating on shares of Cytokinetics in a report on Monday, May 2nd. Piper Jaffray Cos. restated an “overweight” rating and set a $24.00 target price on shares of Cytokinetics in a report on Tuesday, July 12th. Finally, Zacks Investment Research lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Eight equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $17.38.

The stock’s market cap is $386.70 million. The stock’s 50 day moving average price is $9.11 and its 200 day moving average price is $7.95.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.06. On average, equities research analysts expect that Cytokinetics Inc. will post ($1.50) EPS for the current year.

A number of hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP raised its stake in shares of Cytokinetics by 532.5% in the fourth quarter. GSA Capital Partners LLP now owns 117,931 shares of the biopharmaceutical company’s stock worth $1,234,000 after buying an additional 99,287 shares during the period. Matarin Capital Management LLC purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $2,512,000. Finally, Russell Frank Co purchased a new stake in shares of Cytokinetics during the fourth quarter worth about $4,719,000.

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.